ESTRO 2024 - Abstract Book

S478

Clinical - Breast

ESTRO 2024

18. Varghese SS, Sasidharan B, Manipadam MT, Paul MJ, Backianathan S. Radiotherapy in Phyllodes tumour. J Clin Diagn Res. 2017;11(1):XC01 – 3.

19. Liew KW, Siti Zubaidah S, Doreen L. Malignant phyllodes tumors of the breast: a single institution experience. Med J Malaysia. 2018;73(5):297 – 300.

20. Mitus JW, Blecharz P, Jakubowicz J, Reinfuss M, Walasek T, Wysocki W. Phyllodes tumors of the breast. The treatment results for 340 patients from a single cancer Centre. Breast. 2018;43:85 – 90.

21. Park HJ, Ryu HS, Kim K, Shin KH, Han W, Noh DY. Risk factors for recurrence of malignant Phyllodes tumors of the breast. In Vivo. 2019;33(1):263 – 9.

22.. Fou A, Schnabel FR, Hamele-Bena D, Wei XJ, Cheng B, El Tamer M, Klein L, Joseph KA. Long-term outcomes of malignant phyllodes tumors patients: an institutional experience. Am J Surg. 2006;192(4):492 – 5.

413

Digital Poster

CYBERNEO trial: Update of results at 14 years of follow-up

syrine ben dhia 1 , renaud schiappa 2 , joycelin gal 2 , jean-marc ferrero 3 , philippe bahadoran 4 , claire chapellier 5 , pierre yves bondiau 1 1 Antoine Lacassagne center, radiation oncology, nice, France. 2 Antoine Lacassagne center, Department of statistics, nice, France. 3 Antoine Lacassagne center, medical oncology, nice, France. 4 CHU Pasteur, Dermatology, nice, France. 5 Antoine Lacassagne center, medical imagery, nice, France

Purpose/Objective:

The purpose of the phase I "CYBERNEO" trial was to define the efficacy of the CyberKnife®(CK) for locally advanced (stage III) breast tumors combined to a neo-adjuvant treatment with chemotherapy for patients for whom a conservative surgery could not be considered at the onset. Neoadjuvant chemotherapy (NAC) consisted of 6 cycles: 3 cycles of docetaxel and 3 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC). CK was performed during the second cycle of chemotherapy. Breast surgery was performed six to eight weeks later and conventional breast irradiation without boost, afterwards. The main objective was to define the maximum tolerated dose of hypofractionated radiotherapy concurrent with NAC.We present an updated survival data for patients included in this trial and we evaluate the late toxicities of this combination.

Material/Methods:

We updated the survival data of 25 patients treated for a stage III breast cancer between 2007 and 2009 at the Antoine Lacassagne Center in Nice and included in the CYBERNEO trial by recording late toxicities and esthetic results.